Immunicum (IMMU.ST) stock price, revenue, and financials
Immunicum market cap is kr444.7 m.
KR444.7 M
IMMU.ST Mkt cap, 17-Jun-2022Immunicum Gross profit (FY, 2021)9 K
Immunicum Net income (FY, 2021)-133.4 M
Immunicum EBITDA (FY, 2021)-129.1 M
Immunicum EBIT (FY, 2021)-130.1 M
Immunicum Cash, 31-Dec-2021155.3 M
Immunicum EV289.7 M
Immunicum Revenue Breakdown
Immunicum revenue breakdown by business segment: 100.0% from PHARMACEUTICAL BIOLOG/VACCINES
Immunicum Income Statement
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 16.7m | |||
Gross profit | 184.0k | 16.7m | 9.0k | |
R&D expense | (70.7m) | (49.0m) | (47.9m) | (85.8m) |
Operating expense total | (98.0m) | (60.7m) | (85.1m) | (129.1m) |
Depreciation and amortization | (60.0k) | (832.0k) | (887.0k) | (993.0k) |
EBITDA | (97.8m) | (44.0m) | (85.1m) | (129.1m) |
EBIT | (97.8m) | (44.9m) | (86.0m) | (130.1m) |
Interest expense | (14.0k) | (2.9m) | (3.2m) | (3.3m) |
Pre tax profit | (97.9m) | (47.8m) | (89.2m) | (133.4m) |
Net Income | (97.9m) | (47.8m) | (89.2m) | (133.4m) |
Immunicum Balance Sheet
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 443.8m | 14.0m | 167.6m | 155.3m |
Prepaid Expenses | 2.3m | 1.1m | 8.0m | 13.1m |
Inventories | 1.5m | |||
Current Assets | 450.4m | 33.2m | 192.6m | 185.2m |
PP&E | 9.0k | 2.2m | 1.7m | 2.1m |
Goodwill | 108.4m | 108.4m | ||
Total Assets | 450.4m | 37.9m | 728.7m | 721.0m |
Accounts Payable | 31.3m | 1.9m | 10.4m | 11.6m |
Short-term debt | 871.0k | 880.0k | 309.0k | |
Current Liabilities | 43.5m | 11.3m | 48.3m | 27.6m |
Long-term debt | 850.0k | 1.2m | 303.0k | |
Non-Current Liabilities | 850.0k | 32.3m | 19.3m | 36.7m |
Total Debt | 850.0k | 2.1m | 1.2m | 309.0k |
Total Liabilities | 44.3m | 43.6m | 67.6m | 64.2m |
Common Stock | 4.6m | 586.0k | 8.3m | 10.0m |
Additional Paid-in Capital | 731.1m | 258.0m | 1.0b | 1.1b |
Retained Earnings | (329.6m) | (264.5m) | (353.8m) | (487.2m) |
Total Equity | 406.0m | (5.7m) | 661.1m | 656.7m |
Immunicum Cash Flow
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | (97.8m) | (44.9m) | (86.0m) | (130.1m) |
Accounts Receivable | 5.4m | (14.1m) | 22.2m | (4.4m) |
Accounts Payable | 19.6m | (3.3m) | 761.0k | 10.7m |
Cash From Operating Activities | (104.7m) | (57.6m) | (56.6m) | (138.0m) |
Cash From Investing Activities | (809.0k) | 157.3m | (1.4m) | |
Long-term Borrowings | (760.0k) | (725.0k) | (1.9m) | |
Cash From Financing Activities | 419.6m | 67.1m | 50.9m | 127.0m |
Net Change in Cash | 314.9m | 9.6m | 153.6m | (12.3m) |
Immunicum Ratios
| SEK | FY, 2018 |
|---|
